|
US7361336B1
(en)
*
|
1997-09-18 |
2008-04-22 |
Ivan Bergstein |
Methods of cancer therapy targeted against a cancer stem line
|
|
US20040236080A1
(en)
*
|
2001-06-22 |
2004-11-25 |
Hiroyuki Aburatani |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
|
PT1506406E
(en)
*
|
2002-05-23 |
2009-06-03 |
Sunnybrook Health Sciences Ct |
DIAGNOSIS OF HEPATOCELLULAR CARCINOMA
|
|
AU2002338020A1
(en)
*
|
2002-09-04 |
2004-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody against blood-solubilized n-terminal peptide in gpc3
|
|
EP1671645A4
(en)
*
|
2003-09-04 |
2007-07-25 |
Chugai Pharmaceutical Co Ltd |
REMEDY AND DETECTION MEDICINE FOR CANCER OF BILARY TRACT CANCER
|
|
PT1674111E
(en)
*
|
2004-07-09 |
2010-12-15 |
Chugai Pharmaceutical Co Ltd |
Anti-glypican 3 antibody
|
|
DK1800693T3
(en)
|
2004-08-24 |
2013-10-21 |
Chugai Pharmaceutical Co Ltd |
Adjuvant therapy using anti-glypican 3 antibodies
|
|
WO2006046751A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody having modified sugar chain
|
|
WO2006106905A1
(en)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
JPWO2007015529A1
(en)
|
2005-08-03 |
2009-02-19 |
パナソニック株式会社 |
Base station apparatus, communication terminal apparatus, and multicarrier communication method
|
|
US20070087005A1
(en)
*
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
|
US7723043B2
(en)
*
|
2006-01-04 |
2010-05-25 |
Picobella, Lp |
Methods for screening for prostate cancer
|
|
WO2007114319A1
(en)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
Method for control of blood kinetics of antibody
|
|
US9670269B2
(en)
|
2006-03-31 |
2017-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods of modifying antibodies for purification of bispecific antibodies
|
|
AU2008275985B2
(en)
|
2007-07-17 |
2013-09-19 |
E. R. Squibb & Sons, L.L.C. |
Monoclonal antibodies against Glypican-3
|
|
EP3127921A1
(en)
|
2007-09-26 |
2017-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substition in cdr
|
|
CN101874041B
(en)
|
2007-09-26 |
2013-06-19 |
中外制药株式会社 |
Modified antibody constant region
|
|
CA2700986A1
(en)
|
2007-09-28 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican-3 antibody having improved kinetics in plasma
|
|
TWI548418B
(en)
|
2007-12-05 |
2016-09-11 |
Chugai Pharmaceutical Co Ltd |
Anti-NR10 / IL-31RA antibody and its use
|
|
CL2009000647A1
(en)
*
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Pharmaceutical composition for treating or preventing liver cancer comprising a combination of a chemotherapeutic agent and an anti-glypican 3 antibody; agent for attenuating a side effect comprising said antibody; method of treating or preventing liver cancer of a subject.
|
|
EP2708559B1
(en)
*
|
2008-04-11 |
2018-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
TWI440469B
(en)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
|
EP3674317B1
(en)
|
2009-03-19 |
2024-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010107110A1
(en)
|
2009-03-19 |
2010-09-23 |
中外製薬株式会社 |
Antibody constant region variant
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
EP2543730B1
(en)
|
2010-03-04 |
2018-10-31 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
HRP20180421T1
(en)
|
2010-11-17 |
2018-04-20 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
TWI654204B
(en)
|
2010-11-30 |
2019-03-21 |
中外製藥股份有限公司 |
Antibody with calcium-dependent antigen binding ability
|
|
CA2819530C
(en)
|
2010-11-30 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
US20120190049A1
(en)
*
|
2010-12-10 |
2012-07-26 |
University Of Washington Through Its Center For Commercialization |
Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles
|
|
WO2012115241A1
(en)
|
2011-02-25 |
2012-08-30 |
中外製薬株式会社 |
Fcγriib-specific fc antibody
|
|
EP3825325A3
(en)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
|
|
KR20200096692A
(en)
|
2011-09-30 |
2020-08-12 |
추가이 세이야쿠 가부시키가이샤 |
Antigen-binding molecule for promoting elimination of antigens
|
|
CN104093424A
(en)
|
2011-09-30 |
2014-10-08 |
中外制药株式会社 |
Antigen-binding molecules that induce an immune response against a target antigen
|
|
TW201817744A
(en)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
|
|
WO2013047748A1
(en)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
|
|
US20150299313A1
(en)
|
2011-10-05 |
2015-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
|
|
JP6138108B2
(en)
|
2012-02-24 |
2017-05-31 |
中外製薬株式会社 |
Antigen-binding molecule that promotes disappearance of antigen via FcγRIIB
|
|
CN104487457B
(en)
|
2012-05-30 |
2018-01-26 |
中外制药株式会社 |
target tissue specific antigen binding molecule
|
|
CN104520331B
(en)
|
2012-06-01 |
2018-09-07 |
美国政府(由卫生和人类服务部的部长所代表) |
High-affinity monoclonal antibody to Glypican 3 and use thereof
|
|
TWI693073B
(en)
|
2012-12-21 |
2020-05-11 |
日商中外製藥股份有限公司 |
Therapeutic agent for GPC3 target is the effective therapeutic agent for GPC3 target administered to patients
|
|
EP3557260B1
(en)
|
2012-12-21 |
2022-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
|
|
RU2730594C2
(en)
|
2013-09-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Method of producing a polypeptide heteromultiters
|
|
BR112016012094A2
(en)
|
2013-12-04 |
2017-09-26 |
Chugai Pharmaceutical Co Ltd |
antigen binding molecules, whose antigen binding activity varies according to the concentration of compounds and libraries of said molecules
|
|
KR102409014B1
(en)
|
2014-05-08 |
2022-06-14 |
추가이 세이야쿠 가부시키가이샤 |
Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
|
|
US9926377B2
(en)
*
|
2014-05-22 |
2018-03-27 |
Genentech, Inc. |
Anti-GPC3 antibodies and immunoconjugates
|
|
MA40764A
(en)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
THERAPEUTIC AGENT INDUCING CYTOTOXICITY
|
|
CN104829704B
(en)
*
|
2014-12-15 |
2016-08-17 |
河北省科学院生物研究所 |
A kind of glypican GPC3 protein fragments and application thereof and the hybridoma cell strain of preparation
|
|
CA2963760A1
(en)
|
2014-12-19 |
2016-06-23 |
Yoshinao Ruike |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
ES2899894T3
(en)
|
2014-12-19 |
2022-03-15 |
Chugai Pharmaceutical Co Ltd |
Anti-C5 antibodies and methods of use
|
|
AU2015376851B2
(en)
*
|
2015-01-16 |
2020-07-09 |
Minomic International Ltd. |
Glypican epitopes and uses thereof
|
|
MX2017008978A
(en)
|
2015-02-05 |
2017-10-25 |
Chugai Pharmaceutical Co Ltd |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
|
|
ES2967627T3
(en)
|
2015-02-27 |
2024-05-03 |
Chugai Pharmaceutical Co Ltd |
Composition to treat diseases related to IL-6
|
|
WO2016159213A1
(en)
|
2015-04-01 |
2016-10-06 |
中外製薬株式会社 |
Method for producing polypeptide hetero-oligomer
|
|
WO2017002934A1
(en)
|
2015-07-01 |
2017-01-05 |
中外製薬株式会社 |
Gpc3-targeted therapeutic agent administered to patient in whom gpc3-targetd therapeutic ag
|
|
IL257324B
(en)
*
|
2015-08-03 |
2022-08-01 |
Carsgen Therapeutics Ltd |
Antibody against glypican-3 and application thereof
|
|
KR101796688B1
(en)
|
2015-10-29 |
2017-12-01 |
재단법인 목암생명과학연구소 |
Novel Antibody Against Glypican 3, and Pharmaceuitical Composition Comprising the Same
|
|
LT3373968T
(en)
*
|
2015-11-09 |
2024-07-10 |
The Children's Hospital Of Philadelphia |
Glypican 2 as a cancer marker and therapeutic target
|
|
WO2017110981A1
(en)
|
2015-12-25 |
2017-06-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
|
SG11201803989WA
(en)
|
2015-12-28 |
2018-06-28 |
Chugai Pharmaceutical Co Ltd |
Method for promoting efficiency of purification of fc region-containing polypeptide
|
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
TW202248213A
(en)
|
2016-03-15 |
2022-12-16 |
日商中外製藥股份有限公司 |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
|
MA44780A
(en)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
PREPARATION CONTAINING AN ANTIBODY
|
|
TWI831965B
(en)
|
2016-08-05 |
2024-02-11 |
日商中外製藥股份有限公司 |
Compositions for the treatment or prevention of IL-8 related diseases
|
|
WO2018038046A1
(en)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
Gene-modified non-human animal expressing human gpc3 polypeptide
|
|
IL266827B2
(en)
|
2016-11-28 |
2025-04-01 |
Chugai Pharmaceutical Co Ltd |
Ligand-binding molecule having adjustable ligand-binding activity, fusion protein thereof with a ligand, pharmaceutical compositions comprising them, and method of producing them
|
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD FOR PREDICTING AND EVALUATING A THERAPEUTIC EFFECT IN DISEASES ASSOCIATED WITH IL-6 AND NEUTROPHILS
|
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
|
|
MA50534A
(en)
|
2017-11-01 |
2020-09-09 |
Chugai Pharmaceutical Co Ltd |
ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
|
|
TWI880235B
(en)
|
2017-11-28 |
2025-04-11 |
日商中外製藥股份有限公司 |
Ligand-binding molecules capable of regulating ligand binding activity
|
|
AR114112A1
(en)
|
2018-02-15 |
2020-07-22 |
Seattle Genetics Inc |
GLIPICAN 3 ANTIBODIES AND CONJUGATES THEREOF
|
|
JPWO2019230868A1
(en)
|
2018-05-30 |
2021-06-24 |
中外製薬株式会社 |
Single domain antibody-containing ligand-binding molecule
|
|
MX2020013977A
(en)
|
2018-06-22 |
2021-06-15 |
Kite Pharma Inc |
TRANSMEMBRANE CHIMERIC PROTEINS AND THEIR USES.
|
|
AU2019354395A1
(en)
|
2018-10-01 |
2021-05-06 |
Adicet Therapeutics, Inc. |
Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors
|
|
KR20210080460A
(en)
|
2018-10-23 |
2021-06-30 |
드래곤플라이 쎄라퓨틱스, 인크. |
Heterodimeric Fc-fused protein
|
|
WO2020189748A1
(en)
|
2019-03-19 |
2020-09-24 |
中外製薬株式会社 |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
|
BR112021023735A2
(en)
|
2019-06-05 |
2022-01-04 |
Chugai Pharmaceutical Co Ltd |
Antibody cleavage site binding molecule
|
|
JP7716979B2
(en)
|
2019-06-05 |
2025-08-01 |
中外製薬株式会社 |
Protease substrates and polypeptides containing protease cleavage sequences
|
|
KR20220034792A
(en)
|
2019-06-21 |
2022-03-18 |
카이트 파마 인코포레이티드 |
TGF-β receptors and methods of use thereof
|
|
AU2021260960A1
(en)
|
2020-04-22 |
2022-11-24 |
Dragonfly Therapeutics, Inc. |
Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
|
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
|
JP2024537323A
(en)
*
|
2021-10-15 |
2024-10-10 |
コンセプト トゥー メディシン バイオテック カンパニー， リミテッド |
Anti-glypican 3 antibody
|
|
CN121358779A
(en)
|
2023-06-16 |
2026-01-16 |
信立泰(成都)生物技术有限公司 |
Anti-GPC 3 antibody or antigen binding fragment and application thereof
|